^
Association details:
Biomarker:USP42 mutation
Cancer:Pancreatic Cancer
Drug:gemcitabine (DNA synthesis inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

854 / 12 - A pharmaco-pheno-multiomic integration analysis of pancreatic cancer: A highly predictive biomarker model of biomarkers of Gemcitabine/Abraxane sensitivity and resistance

Published date:
03/15/2023
Excerpt:
Tumors exhibiting Gemcitabine/Abraxane resistance associate with increased TRPV6 RNA expression, MUC13 protein expression, and USP42 mutation among others.